Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.69 |
| ▸ | EED | O75530 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 3/20 | 0.57 |
| ▸ | DRD3 | P35462 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3037448 | 1.00 | HTR2C (0.69) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL567956 | 1.00 | HTR2C (0.69) | HTR2CEEDDRD2DRD3HTR2A | |
| Hydrochloric Acid SCHEMBL567518 | 0.98 | HTR2C (0.70) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL11258120 | 0.95 | HTR2C (0.68) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL1810242 | 0.92 | HTR2C (0.82) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL8049667 | 0.92 | HTR2C (0.82) | HTR2CEEDDRD2DRD3HTR2A | |
| SCHEMBL8032211 | 0.92 | HTR2C (0.82) | HTR2CEEDDRD2DRD3HTR2A | |
| Hydrochloric Acid SCHEMBL4573066 | 0.91 | HTR2C (0.82) | HTR2CEEDDRD2HTR2A | |
| SCHEMBL22667384 | 0.85 | HTR2C (0.70) | HTR2CDRD2HTR2A | |
| SCHEMBL18937877 | 0.84 | DRD2 (0.57) | HTR2CEEDDRD2DRD3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | KEZAR LIFE SCIENCES, INC. (US) | 2026-04-14 | — | — | US | disclosed |
| WO-2024213877-A1 | PROCESS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2024-10-17 | — | — | WO | disclosed |
| CN-112262129-B | Triazacyclododecanesulfonamide (\"TCD\") based protein secretion inhibitors | 科智生命科学公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| EP-3765447-B1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | KEZAR LIFE SCIENCES (US) | 2023-07-12 | — | — | EP | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | KEZAR LIFE SCIENCES (US) | 2023-02-14 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-12-22 | — | — | US | disclosed |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2021-03-18 | — | — | US | disclosed |
| EP-2146961-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | NSAB, Filial af NeuroSearch Sweden AB, Sverige (DK) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008127188-A1 | N-OXIDE AND/OR DI-N-OXIDE DERIVATIVES OF DOPAMINE RECEPTOR STABILIZERS/MODULATORS DISPLAYING IMPROVED CARDIOVASCULAR SIDE-EFFECTS PROFILES | ALLBAY AB (SE) | 2008-10-23 | — | — | WO | disclosed |
| US-5594024-A | ANTIDEPRESSANTS; TREATMENT OF NARCOLEPSY, SCHIZOPHRENIA, DRUG ABUSE | THE UPJOHN COMPANY (US) | 1997-01-14 | — | — | US | disclosed |
| US-5462947-A | Nervous system disorders | THE UPJOHN COMPANY (US) | 1995-10-31 | — | — | US | disclosed |
| EP-0641320-A1 | NEW CENTRALLY ACTING SUBSTITUTED PHENYLAZACYCLOALKANES | PHARMACIA & UPJOHN COMPANY (US) | 1995-03-08 | — | — | EP | disclosed |
| WO-1992018475-A2 | SUBSTITUTED PHENYLAZACYCLOALKANES AS CNS AGENTS | THE UPJOHN COMPANY (US) | 1992-10-29 | — | — | WO | disclosed |
| EP-0175452-B1 | 1,3-DISUBSTITUTED PIPERIDINE COMPOUNDS AS NEUROLEPTIC AGENTS | PFIZER INC. (US) | 1988-09-21 | — | — | EP | disclosed |
| US-4623728-A | NERVOUS SYSTEM DISORDERS | PFIZER INC. (US) | 1986-11-18 | — | — | US | disclosed |
| US-4593037-A | Compound substituted with phenyl rings | PFIZER INC. (US) | 1986-06-03 | — | — | US | disclosed |
| EP-0175452-A1 | 1,3-Disubstituted piperidine compounds as neuroleptic agents | PFIZER INC. (US) | 1986-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11578055-B2 | Triazacyclododecansulfonamide (“TCD”)-based protein secretion inhibitors | SEC61B, SEC61A1, SEC61G | HTR2C 4577/4885EED 2146/4885DRD2 2954/4885 |
| US-20220402891-A1 | TRIAZACYCLODODECANSULFONAMIDE (TCD)-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR2C 4504/4885EED 2350/4885DRD2 3081/4885 |
| US-12600711-B2 | Triazacyclododecansulfonamide (TCD)-based protein secretion inhibitors | CD274, CD40, ICOS | HTR2C 4074/4885EED 2034/4885DRD2 975/4885 |
| US-20210078974-A1 | TRIAZACYCLODODECANSULFONAMIDE (\"TCD\")-BASED PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | HTR2C 4460/4885EED 2332/4885DRD2 2649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.